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Abstract
AIM: To investigate the expression pattern of clusterin in
colorectal adenoma-carcinoma-metastasis series, and to
explore the potential role of clusterin in multistage colorectal
tumorigenesis and progression.
METHODS: A colorectal carcinoma (CRC)-tissue microarray
(TMA), which contained 85 advanced CRCs including 43
cases of Dukes B, 21 of Dukes C and 21 of Dukes D tumors,
were used for assessing the expression of clusterin (clone
41D) and tumor cell apoptotic index (AI) by immunohist-
ochemistry and TUNEL assay, respectively. Moreover the
potential correlation of clusterin expression with the patient’s
clinical-pathological features were also examined.
RESULTS: The positive staining of clusterin in different
colorectal tissues was primarily a cytoplasmic pattern.
Cytoplasmic overexpression of clusterin was detected in
none of the normal colorectal mucosa, 17% of the adenomas,
46% of the primary CRCs, and 57% of the CRC metastatic
lesions. In addition, a significant positive correlation between
overexpression of clusterin and advanced clinical (Dukes)
stage was observed (P<0.01). Overexpression of
cytoplasmic clusterin in CRCs was inversely correlated
with tumor apoptotic index (P<0.01), indicating the anti-
apoptotic function of cytoplasmic clusterin in CRCs.
CONCLUSION: These data suggests that overexpression
of cytoplasmic clusterin might be involved in the tumorigenesis
and/or progression of CRCs. The anti-apoptotic function of
cytoplasmic clusterin may be responsible, at least in part, for
the development and biologically aggressive behavior of CRC.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Colorectal carcinoma (CRC) is one of the most common
human cancers and a major cause of cancer-related death
in the developed countries[1]. The incidence of CRC in China
including urban Shanghai, is increasing rapidly particularly
in the last two decades[2]. At present, CRC is the fourth leading
cause of cancer-related death in China. Although CRC has
been widely studied and the development of this cancer is
most probably a multistep process involving multiple genetic
changes, the understanding of the precise pathogenic
mechanisms by which normal colorectal epithelial cells become
malignant cells, is far from being thoroughly understood.
Clusterin, also known as apolipoprotein J (ApoJ), is a
heterodimeric highly conserved and secreted glycoprotein
being expressed in a wide variety of tissues and found in
many body fluids. Clusterin has been implicated in diverse
normal biological processes such as sperm maturation, lipid
transportation, tissue remodeling, membrane recycling, cell-
cell and cell-substratum interactions and cell apoptosis[3-7].
Recently, a potential oncogenic role of clusterin in the
development and/or progression of several human cancers
has been examined. Increased expression of clusterin was
detected in prostate, renal cell and lung cancer[8,9]. Expression
of  clusterin has been positively associated with the aggr-
essive nature of breast cancer, while the expression of
clusterin in normal breast epithelial cells has been undete-
ctable[10].
Moreover, increased expression of clusterin in murine
and human intestinal neoplasia has been reported[11]. However,
to date, the expression pattern of clusterin and its oncogenic
role in the development of human CRC are unclear. In the
present study, the expression dynamics of clusterin in an
array of  human colorectal tissue, normal and pathological,
non-neoplastic and neoplastic, were investigated using a tissue
microarray (TMA) assay. The potential correlation between
clusterin expression and critical clinical/pathological features
of CRC were also assessed.
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MATERIALS AND METHODS
Patients and tissues
Eighty-five surgically resected CRC specimens were obtained
from the First Affiliated Hospital of  Sun Yat-Sen University,
Guangzhou, China as previously described[12]. The age of these
patients ranged from 36 to 85 years at the time of surgery
(mean age, 59.6 years) and the male/female ratio was 1.2:1.
All cases selected were moderately differentiated adenocar-
cinomas. According to Dukes staging system, the distribution
for clinical stage of these CRCs were as follows: Dukes B,
43 cases; Dukes C, 21 cases; Dukes D, 21 cases. A previously
constructed TMA block containing all 85 CRC cases was
used for immunohistochemical (IHC) and TUNEL assay[12].
In this CRC-TMA, six samples from different pathologic
and progressive loci were selected from each of the 85
advanced CRC cases. Tissue samples from adjacent non-
neoplastic mucosa, primary carcinomas in inner layers (confined
to the layer of mucosa and/or submucosa), muscularis layer
and serosa layer of the bowel wall were selected for all CRC
cases. Tissue samples from matched adenomatous polyps
were obtained from 22 cases (tubular, n = 12; tubulo-
villous, n = 3; and villous, n = 7) and tissues from matched
lymph node and distant metastases were selected from 21
cases.
IHC staining
IHC studies were performed using a standard streptavidin-
biotin-peroxidase complex method[12]. In brief, TMA sections
were deparaffinized and rehydrated. Endogenous peroxidase
activity was blocked with 0.3% hydrogen peroxide for 20 min.
For antigen retrieval, CRC-TMA slides were microwave-
treated in 10 mmol/L citrate buffer (pH 6.0) for 10 min.
Nonspecific binding was blocked with 10% normal rabbit
serum for 10 min. The TMA slides were incubated with a
monoclonal anti-clusterin (Clone 41D; Upstate Biotechnology,
Lake Placid, NY, USA, 1:200 dilution) and a monoclonal
anti-Ki-67 (Dako, Glostrup, Denmark, 1:100 dilution) for
60 min at 37 ℃ in a moist chamber, respectively. The slides
were then sequentially incubated with a biotinylated rabbit
anti-mouse immunoglobulin at a concentration of 1:100
for 30 min at 37 ℃ and subsequently reacted with a
streptavidin-peroxdase conjugate for 30 min at 37 ℃ and
3’-3’ diaminobenzidine as a chromogen substrate. The
nucleus was counterstained using Meyer’s hematoxylin. The
slides were dehydrated and coverslipped. Negative controls
were performed by replacing the primary antibody with mouse
IgG. Known immunostaining positive slides of ovarian cancer
were used as positive controls.
For evaluation of  the clusterin IHC staining in different
colorectal tissues, the positive expression of clusterin in non-
malignant and malignant tissues was primarily a cytoplasmic
pattern (Figure 1). Both staining intensity and positive areas
were recorded. A staining index (values 0-12), obtained as
the intensity of clusterin positive staining (negative = 0,
weak = 1, moderate = 2, or strong = 3 scores) and the
proportion of immunopositive cells of interest (<25% = 1;
25-50% = 2; >50-75% = 3; >75% = 4 scores), was calculated.
The status of Ki-67 nuclear expression was counted as the
percentage of Ki-67 positive staining cells in each case. The
immunostained slides of TMA were reviewed independently
twice and intra-observer disagreements (<10%) were reviewed
a third time, followed by a conclusive judgment.
TUNEL assay
The fluorescent TUNEL staining was performed using a
death detection kit (Roche Diagnostic GmbH, Mannheim,
Germany) according to the manufacturer’s instructions.
Briefly, the rehydrated TMA section was microwave-treated
in 10 mmol/L citrate buffer (pH 6.0) for 5 min. After
washing in phosphate-buffered saline (PBS), the specimen
was incubated with a mixture of TdT solution (enzyme
solution) and FITC labeled dUTP solution (label solution)
in a humidified chamber in the dark at 37 ℃ for 60 min.
After washing, the slide was examined with a Zeiss Axiophot
fluorescence microscope. Negative controls were obtained
by replacing the TdT solution with distilled water. The
presence of clear nuclear staining (TUNEL-positive, green
color) was indicative of apoptotic cells (Figure 2). Apoptotic
bodies were defined as TUNEL-positive, single, relatively
large (≥ 4 µm diameter) and rounded bodies existing in
extra- or intra-tumor cells with intense staining. The number
of TUNEL-positive tumor cell nuclei was counted and the
apoptotic index (AI) was determined as the percentage of
apoptotic cells in the tumor. Because the mean value of AI
for all informative samples in this study was 1.9, tumors
were classified into two groups according to their AI: low
AI group (AI≤1.9) and high AI group (AI>1.9).
To investigate the correlation of  clusterin expression
Figure 1  Expression of clusterin in different pathological loci of one Dukes C
colorectal carcinoma with matched lymph node metastasis. Strong cytoplasmic
staining of clusterin was observed in primary carcinoma in the mucosa layer of
the bowel wall, while its adjacent normal mucosa showed a weak positivity
(A). Strong cytoplasmic staining of clusterin was also observed in carcinomas
in muscularis propria (B), and serosa layer (C) and its matched lymph node
metastasis (D) in the same primary carcinoma (original magnification ×100).
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and cell apoptosis, a simultaneous IHC staining with anti-
clusterin antibody and fluorescent TUNEL staining was
performed. First, clusterin immunostaining was performed
as described above. The second antibody was used with a
Cy3 (orange) labeled goat anti-mouse polyclonal IgG (SC-
20009, Santa Cruz Biotechnology, Santa Cruz, CA, USA,
1:100 dilution) and incubated with the section, in the dark,
at 37 ℃ for 45 min. The slide was washed with PBS and
then counterstained with 1 µg/mL DAPI in an anti-fade
solution, then examined with a Zeiss Axiophot fluorescence
microscope equipped with a dual band pass filter for
simultaneous visualization of FITC and Spectrum Orange
signals using ×10 and ×40 objectives.
Statistical analysis
For statistical evaluation, 2 test for trend was used to assess
the differential expression of clusterin in different colorectal
tissues. 2 test was used to assess the statistical significance
of the association of the expression of clusterin with the
patient’s clinico-pathological parameters and its correlation
with apoptotic indices. Unpaired t test was used to assess the
statistical significance of the differential expression of Ki-
67 between groups with and without clusterin overexpression.
P values lesser than 0.05 were considered significant.
RESULTS
Clusterin expression in colorectal tissues
The expression of clusterin was investigated by IHC in a
CRC-TMA which contained adjacent normal colorectal
mucosa and different colorectal lesions including premalignant
colorectal adenoma, primary CRC, and metastatic CRC.
The antibody (clone 41D) used in this study was a monoclonal
anti-human clusterin, which recognizes the a subunit of the
clusterin heterodimer. The expression pattern of clusterin
in epithelial cells of different colorectal tissues was heterogeneous
with different staining indices in the cytoplasm. Because
the staining index of cytoplasmic expression of clusterin in
all 76 informative normal colorectal mucosa was less or
equal to 6, we designated the staining index of  0-6 as the normal
expression of clusterin. Overexpression of clusterin was
defined when staining index was more than 6 (Figure 1B-D).
Using this designation, the overexpression of cytoplasmic
clusterin was detected in 4/20 (17%) informative colorectal
adenomas, 39/85 (46%) primary CRCs, and 20/35 (57%)
lymph node and/or distant metastatic lesions, respectively.
The increasing frequencies of clusterin overexpression from
normal colorectal mucosa, to benign adenomas and primary
CRC, and to CRC metastatic lesion were significant (P<0.01,
2 trend test, Table 1). However, no heterogeneous expression
of  clusterin was observed among the different layers of
the bowel wall of CRC.
Table 1 Expression of clusterin in normal colorectal mucosa and in
benign and malignant colorectal tumors1
Clusterin
     Informative cases
    Normal expression          Overexpression
Normal mucosa 76             76 (100%)   0 (0)
Adenoma 20             16 (83%)   4 (17%)
Primary carcinoma 85             46 (54%) 39 (46%)
Metastases 35             15 (43%) 20 (57%)
1Values are n (%). A significant increasing frequency of overexpression of clusterin
was observed in adenoma, in primary carcinoma and in metastatic lesion (P<0.01,
2 test for trend.
Association of clusterin expression with clinico-pathological
features
The association of cytoplasmic expression of clusterin and
patient’s clinico-pathological features were further studied.
The results showed that cytoplasmic overexpression of
clusterin in primary CRC was significantly associated with
the patient’s clinical stage. Overexpression of clusterin was
detected in 25/42 (60%) CRCs in late clinical stages (Dukes
C or D stage), which was significantly higher than that in
early stage (Dukes B) (14/43, 33%) (P<0.05, 2 test). But
no significant association was found between clusterin
expression and other clinico-pathological features, such as
patient’s gender, age, and tumor location (data not shown).
Correlation of clusterin expression with cell apoptosis
Because clusterin has been associated with the process of
cell apoptosis[7], the TUNEL assay was used to study the
status of apoptosis in these CRC cohorts. A high apoptotic
index was detected in 32/83 (39%) of  the informative
CRCs. The results showed that the frequency of high
apoptotic index was significantly higher in tumors with a
Figure 2  Double fluorescent staining of clusterin and TUNEL in colorectal
carcinoma. A: A colorectal carcinoma with overexpression of cytoplasmic
clusterin (red) showed low apoptotic index (AI), where apoptosis (green signal
indicated with arrows) was observed in only one tumor cell; B: High AI was
observed in a CRC with negative expression of cytoplasmic clusterin, where
several TUNEL positive cells (green nuclei indicated with arrows) were observed.
(Left figure: original magnification ×100; Right figure: ×400).
A B
normal expression of  clusterin (24/46 cases, 52%) than
that in cases with overexpression of clusterin (8/37, 22%)
(P<0.01, Table 2). In addition, the double fluorescent staining
with clusterin and TUNEL showed that apoptosis was more
likely to occur in tumor cells with low level expression of
clusterin, but not in tumor cells with high level of expression
of clusterin (Figure 2A). In general, cell apoptosis in CRC
was inversely correlated with the overexpression of clusterin.
Table 2  Correlation of expression of clusterin and apoptotic index
(AI) in colorectal carcinomas
Apoptotic index (AI)
Clusterin            Informative       High              Low     P1
case
Overexpression (%)   37      8 (22)             29 (78) <0.01
Normal expression (%)   46    24 (52)             22 (48)
12 test.
Correlation of clusterin expression with cell proliferation
To identify whether or not the overexpression of  clusterin
was associated with cell proliferation in colorectal cancer,
we further analyzed the potential correlation between the
expression of clusterin and cell proliferation (via monoclonal
anti-ki-67). For the 39 cases with overexpression of  clusterin,
an average of 36.7% of the tumor cells was positively stained
with Ki-67 antibody, which was similar to that (average of
38.1% cells) in the remaining 46 tumors with normal expression
of clusterin (P>0.05, unpaired-t test).
DISCUSSION
Most CRCs arise from adenomas through an archetypal
pathogenic pathway, the adenoma-carcinoma-metastasis
sequence. CRC is a well-studied example of multistep
tumorigenesis and, therefore, offers an excellent model to
investigate the accumulation of genetic alterations during
this neoplastic process. In the present study, we used a
previously constructed TMA-CRC series[12], which was
composed of multiple colorectal tissues from different
pathological loci of the same patient samples. These samples
represented the full spectrum of CRC pathogenesis, including
adjacent normal mucosa, benign adenoma, primary carcinomas
and lymph node and distant metastases. Overall, overexp-
ression of  clusterin was observed to increase from the earliest
detectable stage of  abnormal growth, adenoma, to primary
carcinoma and to local lymph node or distant metastases.
These findings provide evidence that the increased expression
of clusterin is involved in CRC tumorigenesis and
progression. In addition, we found that the overexpression
of cytoplasmic clusterin in primary CRCs was strongly
associated with patients’ Dukes stage, i.e., overexpression
of clusterin in cytoplasm was more frequently detected in
later Dukes stages (C and D) when compared to that in
Dukes B. These results suggest that overexpression of
cytoplasmic clusterin in CRC may facilitate cancer cell invasion
and metastasis. Previous studies have also documented that
increased expression of clusterin was involved in the develop-
ment and progression of several types of carcinomas, including
breast, prostate and kidney carcinomas[8-10]. Taken together,
clusterin expression may be an important prognostic factor
of  aggressive nature of  several human cancers, including
CRC.
Although some hypothetical indirect tumorigenic
functions of clusterin could be speculated due to its
implication in cell-cell and cell-substratum interactions, and
in a cytoprotective role in plasma membrane[13], the biological
role in tumorigenesis remains unclear. Trougakos and colleagues
have reported that clusterin knockdown in human cancer
cell, by using small interfering RNA, may induce higher rates
of spontaneous apoptosis and significantly reduce tumor
cell growth [14]. Other groups have reported a significant increase
in cell death after transfection of antisense oligonucleotides
into clusterin[15]. Some authors have suggested that the anti-
apoptotic activity of clusterin may account for the genesis and
biologically aggressive behavior of  several cancer cells[10,16].
In the present study, a significant inverse correlation of
clusterin expression and apoptosis was revealed in our CRC
cohorts, i.e., a lower apoptotic index was more likely to be
observed in CRCs with overexpression of  cytoplasmic
clusterin than in those with normal expression of  this protein.
Furthermore, tumor cells undergoing apoptosis were often
found with a lower expression level of cytoplasmic clusterin
when compared to their adjacent tumor cells without
apoptosis. These results demonstrate as well an anti-apoptotic
function of clusterin in CRCs.
Clusterin has been implicated in apoptosis as a pro-or
anti-apoptotic molecule in various models under different
circumstances, in which clusterin may exert different
biological functions[13]. Recently, it has become increasingly
clear that the clusterin gene codes for a family of different
protein isoforms[17], which are derived, by alternative post-
translational processes, from the same precursor of 53 ku
protein[18,19]. Different isoforms of  clusterin have been
previously reported to occur, in apoptotic and surviving cells,
in the regressing rat ventral prostate[4]. Nuclear clusterin has
been suggested as a cell death protein[20]. Recently, data from
in vivo and in vitro studies of clusterin in colon tumorigenesis
have demonstrated that nuclear clusterin was predominantly
expressed in normal mucosa of  colon and may act as a pro-
apoptosis protein, while cytoplasmic clusterin may function
as an anti-apoptosis protein[16]. In the colorectal tumors of
the present study, the antibody (clone 41D) used was a
monoclonal anti-human clusterin, which recognizes the 
subunit of the clusterin heterodimer. The staining of
clusterin in colorectal epithelial cells was only a cytoplasmic
pattern and nuclear staining was not observed in colorectal
epithelial tissues, non-neoplastic and neoplastic. Although
further studies are needed to determine the exact function
of  the different isoforms of  clusterin and how the signaling
pathways through clusterin gene are regulated, the present
study has demonstrated: (1) a cytoplasmic expression pattern
of clusterin in the full spectrum of CRC pathogenesis, from
normal mucosa, to adenoma, to carcinoma, to metastasis; and
(2) an increased level of cytoplasmic clusterin was directly
associated with decreased cell apoptosis, increased aggres-
siveness and metastasis, suggesting that this protein may
play an important role in the multistage development and/or
progression of human CRCs.
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